Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Global Knee Replacement Market to Reach USD 17.81 Bn. by 2034, Driven by Rising Osteoarthritis Prevalence, Rapid Adoption of Robotic-Assisted Surgery, and Advancements in Smart Implant Technologies Says Maximize Market Research
- The Kenaitze Indian Tribe Notifies Individuals of Data Security Incident
- Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →